Clinical Trials Logo

Primary Progressive Aphasia clinical trials

View clinical trials related to Primary Progressive Aphasia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05860647 Completed - Clinical trials for Primary Progressive Aphasia

Transmagnetic Stimulation Pilot in Primary Progressive Aphasia

TMS in PPA
Start date: October 2, 2023
Phase: N/A
Study type: Interventional

Frontotemporal degeneration (FTD) is a non-Alzheimer's dementia that is the 2nd most common cause of dementia in the United States. FTD may present with focal language symptoms that are clinically described as primary progressive aphasia (PPA). There are two types of PPA associated with FTD-semantic variant primary progressive aphasia (SV-PPA) and nonfluent/agrammatic variant primary progressive aphasia (NFV-PPA). Both diseases are progressive neurodegenerative disease processes that compromise dominant hemisphere large scale brain network function, ultimately resulting in mutism. There are currently no FDA-approved treatments for PPA and management is mostly supportive. In combination with resting state functional MRI (rs-fMRI), transcranial magnetic stimulation (TMS) with intermittent theta burst stimulation (iTBS) offers a non-invasive alternative to pharmacotherapy in persons with PPA. In our prior studies of Alzheimer's disease (AD) and Lewy body Dementia (LBD) subjects, investigators have determined that the anterior temporal pole (area TGd and TGv) is an area that is commonly dysfunctional in dementia. The investigators have already embarked upon an fMRI guided study of iTBS in early stage Alzheimer's disease where subjects received a series of 5 treatments to distinct brain regions inclusive of area TGd. The investigators propose a case study of 3 PPA studies where rs-fMRI is applied to the large-scale language networks.

NCT ID: NCT05697380 Completed - Alzheimer Disease Clinical Trials

CB3 Pilot (Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia)

CB3 Pilot
Start date: June 1, 2021
Phase: N/A
Study type: Interventional

This study will evaluate evidence-based treatments for adults with mild Primary Progressive Aphasia (PPA). The aim of the study is to help identify efficacious communication and quality of life interventions for those with PPA and their care-partners. Participants with a diagnosis of PPA and their actively-engaged care partners will be involved in the study for 12 months. Each participant will receive a iPad equipped with the necessary applications and features for the study. Participants will complete evaluations, speech therapy sessions with a speech and language therapist, and sessions with a licensed social worker or related clinician. They will have access to Communication Bridge, a personalized web application to practice home exercises that reinforce treatment strategies. There are no costs to participate in this study.

NCT ID: NCT05615922 Completed - Clinical trials for Primary Progressive Aphasia

Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)

Start date: December 24, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish the feasibility of a program of remotely supervised transcranial direct current stimulation (RS-tDCS) paired with language skills practice for people living with the semantic or logopenic variants of primary progressive aphasia (PPA). There are currently no established standard-of-care treatments for PPA. This study will evaluate whether RS-tDCS combined with language skills practice is a feasible study design for individuals with PPA.

NCT ID: NCT05537688 Completed - Alzheimer Disease Clinical Trials

Identification of Graphic Markers of Neurocognitive Disorders (MG)

MG
Start date: June 27, 2022
Phase:
Study type: Observational

The diagnosis of neurocognitive disorders such as early Alzheimer's disease (AD) or primary progressive aphasia (PPA) is particularly difficult and constantly evolving, often leading to diagnostic erraticity. However, several studies have shown that graphic parameters are affected in people with moderate to severe Alzheimer's disease. The use of new technologies in the study and analysis of the abilities of people with neurodegenerative diseases is increasingly recommended. The use of a digital tablet with a stylus makes it possible to objectivize the kinematic parameters of writing (pressure, inclination, speed, jerk, time of writing task) and thus would allow a low-cost diffusion of this technology in particular by including it in already existing screening batteries. The overall objective of the project is to characterize and compare the graphical markers of a writing task, either language-based (writing words, non-words, sentences) or non-language-based (drawing shapes), in patients with PPA, early-stage Alzheimer's disease (i.e., at the stage of minor neurocognitive disorders and major neurocognitive disorders at the beginning of the disease), and in people with no cognitive disorders.

NCT ID: NCT05525377 Completed - Alzheimer Disease Clinical Trials

Better Living With Non-memory-led Dementia

Start date: June 21, 2022
Phase: N/A
Study type: Interventional

This is a feasibility study on the effects of an online-based training and education programme for carers of people with posterior cortical atrophy (PCA), primary progressive aphasia (PPA) and behavioural-variant frontotemporal dementia (bvFTD).

NCT ID: NCT04939818 Completed - Parkinson Disease Clinical Trials

Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders

RHAPSODY
Start date: June 14, 2021
Phase:
Study type: Observational [Patient Registry]

The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by the average length of speech elicitation for each speech task during the first week of self-assessment. Secondary objectives include (1) evaluating the reliability of speech tasks in the remote self-administered setting, as measured by the intra- and inter-subject variance; (2) accessing the adherence of speech tasks in this setting, as measured by the subject average fraction of days during the first week, where at least one task response is submitted; (3) evaluating the feasibility of using speech tasks in the setting of a telemedicine videoconference, as measured by the average length of speech elicited in each group; (4) evaluate whether a set of acoustic and linguistic patterns can detect each indication, compare to either a control group or all other indications, as measured by the area under the receiver operating characteristic curve (AUC), sensitivity, specificity and Cohen's kappa of the relevant binary classifier; (5) evaluating how the performance of such algorithms can be impacted by speaker and environment covariates, as measured by the Kendall rank correlation coefficient of the AUC of each classifier and each of age group, gender and speech-to-reverberation modulation energy ratio.

NCT ID: NCT04726527 Completed - Alzheimer Disease Clinical Trials

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia

PPA
Start date: March 15, 2012
Phase:
Study type: Observational

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

NCT ID: NCT04720001 Completed - Alzheimer Disease Clinical Trials

Florbetaben PET Imaging in PPA

Start date: August 23, 2018
Phase:
Study type: Observational

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

NCT ID: NCT04431401 Completed - Clinical trials for Primary Progressive Aphasia

rTMS Treatment of Primary Progressive Aphasia

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Primary Progressive Aphasia (PPA) is a neurodegenerative disease in which language function is gradually and progressively impaired. Patients will eventually be disabled in communication and have cognition deficits, which put a heavy burden not only on their families but also on the whole society. However, no effective treatment for PPA has been explored so far. The current clinical randomized trial is to study the safety and efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of PPA. Also, multi-modality of neuroimaging techniques, such as functional MRI and PET will be used to investigate brain network changing in this procedure.

NCT ID: NCT04412083 Completed - Caregiver Burnout Clinical Trials

PPA Tele-Savvy: A Pilot Study of an Online Intervention for Caregivers of Persons Living With PPA

Start date: July 30, 2020
Phase: N/A
Study type: Interventional

The primary goal of this pilot project is to adapt an evidence-informed on-line psychoeducation program (Tele-Savvy) to address the unique challenges facing informal caregivers of those living with PPA and geared toward achieving caregiver mastery in this population.